Monthly Archives: May 2019

Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual Meeting

Study Evaluating Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA® EAGAN, MN — May 16, 2019 — Biothera Pharmaceuticals, Inc., which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present primary clinical data from its phase 2 study in chemo-refractory metastatic triple negative breast cancer at the American Society of Clinical Oncology (ASCO) 2019 annual meeting, May...

Read More